• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NanoViricides, Inc. Common Stock (NY:NNVC)

    1.140 -0.050 (-4.21%)
    Streaming Delayed Price Updated: 12:25 PM EST, Dec 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about NanoViricides, Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    2 Small-Cap Biotechs That Could Reward Patient Investors ↗
    Via MarketBeat
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
    Via ACCESS Newswire
    News headline image
    NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
     
    Via Benzinga
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at Spartan Capital Investor Conference 2025
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
    Via ACCESS Newswire
    BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
    Via ACCESS Newswire
    News headline image
    A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
    Via ACCESS Newswire
    News headline image
    NanoViricides, Inc. Has Filed its Annual Report
    Via ACCESS Newswire
    News headline image
    RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
    Via ACCESS Newswire
    InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
    Via ACCESS Newswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.